A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

NCT02879617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer NSCLC

Interventions

DRUG: durvalumab

Sponsor

Academic Thoracic Oncology Medical Investigators Consortium

Collaborators

[object Object]